ABL Bio

Privately held: no public share price · South Korea

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Claudin 18.2 (CLDN18.2) x 4-1BBMultispecific antibody
Gastric Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2030 (1)
March 2030 (1)
givastomigPhase 2Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Est. primary completion 2030-03 · NCT07432295 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.